BBIO CEO Haldea files Form 4 detailing November 2025 share sales

Q: What did BridgeBio Pharma (BBIO) disclose in this Form 4 filing?

The filing reports that Chief Executive Officer and director Kumar Haldea sold shares of BridgeBio Pharma, Inc. common stock on 11/20/2025 in several open-market transactions and provides updated information on his direct and indirect beneficial ownership.

Q: How many BridgeBio (BBIO) shares did the CEO sell on 11/20/2025?

Kumar Haldea reported three sales of common stock on 11/20/2025 : 6,401 shares at a weighted average price of $64.9706 , 14,299 shares at $65.904 , and 5,456 shares at $66.7129 , each reflecting multiple trades within stated price ranges.

Q: What are the updated BridgeBio (BBIO) share holdings of the CEO after these sales?

After the reported transactions, Kumar Haldea directly owned 228,776 shares of BridgeBio common stock. He also had indirect beneficial ownership of 795,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,598,447 shares through the Kumar Haldea Revocable Trust , where he acts as co-trustee.

Q: How were the sale prices for the BridgeBio (BBIO) CEO’s trades determined?

The filing explains that each reported price is a weighted average sale price . For example, $64.9706 reflects shares sold between $64.49 and $65.48 , and similar ranges are provided for the other weighted average prices. Detailed trade-by-trade information is available from the reporting person upon request.

Q: What does the CEO state about beneficial ownership of BridgeBio (BBIO) shares held in trusts?

The filing notes that Kumar Haldea disclaims beneficial ownership of shares held by the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust except to the extent of his pecuniary interest, and it clarifies that this report is not an admission of beneficial ownership for Section 16 or other purposes.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) Chief Executive Officer and director Kumar Haldea reported open-market sales of the company’s common stock on 11/20/2025 under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2025. He sold 6,401 shares at a weighted average price of $64.9706, 14,299 shares at a weighted average price of $65.904, and 5,456 shares at a weighted average price of $66.7129, with each price reflecting sales across specified ranges. Following these transactions, Haldea directly held 228,776 shares and also had indirect beneficial ownership of 795,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,598,447 shares through the Kumar Haldea Revocable Trust, where he serves as co-trustee and disclaims beneficial ownership except to the extent of any pecuniary interest.

Insider Trade Summary

Net Seller: 26,156 shares ($1,722,224)

Net Sell 5 txns

Insider Kumar Neil

Role Chief Executive Officer

Sold 26,156 shs ($1.72M)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,401	$64.9706	$416K
Sale	Common Stock	14,299	$65.904	$942K
Sale	Common Stock	5,456	$66.7129	$364K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 248,531 shares (Direct); Common Stock — 795,686 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.)

Footnotes (1)

This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. Represents the weighted average sale price of the shares sold from $64.49 to $65.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $65.49 to $66.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $66.49 to $67.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

Form 4 Insider Transactions: What Each Field Means →

11/24/2025 - 06:46 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last)

(First)

(Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/20/2025		S⁽¹⁾		6,401	D	$64.9706⁽²⁾	248,531	D
Common Stock	11/20/2025		S⁽¹⁾		14,299	D	$65.904⁽³⁾	234,232	D
Common Stock	11/20/2025		S⁽¹⁾		5,456	D	$66.7129⁽⁴⁾	228,776	D
Common Stock								795,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.⁽⁵⁾
Common Stock								4,598,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

2. Represents the weighted average sale price of the shares sold from $64.49 to $65.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. Represents the weighted average sale price of the shares sold from $65.49 to $66.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

4. Represents the weighted average sale price of the shares sold from $66.49 to $67.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

5. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did BridgeBio Pharma (BBIO) disclose in this Form 4 filing?

The filing reports that Chief Executive Officer and director Kumar Haldea sold shares of BridgeBio Pharma, Inc. common stock on 11/20/2025 in several open-market transactions and provides updated information on his direct and indirect beneficial ownership.

How many BridgeBio (BBIO) shares did the CEO sell on 11/20/2025?

Kumar Haldea reported three sales of common stock on 11/20/2025: 6,401 shares at a weighted average price of $64.9706, 14,299 shares at $65.904, and 5,456 shares at $66.7129, each reflecting multiple trades within stated price ranges.

Were the BridgeBio (BBIO) CEO’s stock sales under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 sales plan adopted by Kumar Haldea on March 31, 2025, and the relevant checkbox indicating a Rule 10b5-1(c) plan is marked.

How were the sale prices for the BridgeBio (BBIO) CEO’s trades determined?

The filing explains that each reported price is a weighted average sale price. For example, $64.9706 reflects shares sold between $64.49 and $65.48, and similar ranges are provided for the other weighted average prices. Detailed trade-by-trade information is available from the reporting person upon request.

What does the CEO state about beneficial ownership of BridgeBio (BBIO) shares held in trusts?

The filing notes that Kumar Haldea disclaims beneficial ownership of shares held by the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust except to the extent of his pecuniary interest, and it clarifies that this report is not an admission of beneficial ownership for Section 16 or other purposes.